The involvement of antihypertensive therapy in the pathology of hypertension associated male erectile dysfunction is unclear. Stroke prone spontaneously hypertensive rats (SHRSP) were treated chronically with the angiotensin converting enzyme (ACE) inhibitor captopril or placebo, normotensive rats served as controls. Mean arterial and intracavernosal pressure were measured during the induction of erection by autonomic ganglion stimulation. SHRSP-placebo treated rats were hypertensive and had a blunted erectile response. Captopril treatment returned both the blood pressure and erectile response to control levels. Therefore, ACE inhibitor therapy may not be responsible for the erectile dysfunction observed in treated hypertensive subjects.
Introduction
Penile erection occurs when the vascular smooth muscle cells, located in the cavernosal arterioles and cavernous sinuses relax, leading to an increase in blood flow into the cavernous sinuses under the driving force of mean arterial pressure (MAP). As the cavernous sinuses fill with blood the venoocclusive mechanism is activated which limits blood outflow from the penis. Thus, the combination of increased inflow and decreased outflow results in the rigidity of the corpus cavernous necessary for erection.
Hypertension and cardiovascular disease are risk factors for male erectile dysfunction (ED). 1, 2 It is becoming clear that the incidence of ED is associated with the severity and duration of hypertension. 3 Treatment with antihypertensive agents may cause or exacerbate existing erectile dysfunction. 4, 5 Some studies point towards ACE inhibitors, in particular, as playing as causative role. 6 However, other recent studies have suggested that the use of ACE inhibitors may be beneficial in improving ED. 7 The aim of this study was to assess the effects of hypertension and ACE inhibition on male ED using rat model of genetic hypertension the SHRSP.
Methods
Male SHRSP were obtained from the breading colony at the Medical College of Georgia, Augusta, GA. Beginning at six weeks of age, SHRSP were treated captopril (50 mg=day) in the drinking water for six weeks prior to experimentation, placebo treated SHRSP received tap water. Normotensive male Sprague Dawley rats were obtained from Harlan Laboratories to serve as controls. All rats were maintained on a 12-hour light dark cycle and were allowed access to normal rat chow ad libitum. Systolic blood pressure was measured by tail-cuff prior to experimentation.
Erectile response measurements
The methods used to measure intracavernosal pressure and mean arterial pressure have been described previously. 8 Briefly, rats were anesthetized with ketamine (87 mg=kg) and xylazine (13 mg=kg) and anesthesia was maintained with supplemental doses of ketamine. The left carotid artery was canulated to allow for continuous monitoring of MAP. The right major pelvic ganglion was exposed through an abdominal incision. The shaft of the penis was then cleared of skin and fascia and the right corpus cavernosum was canulated to allow for continuous monitoring of intracaversonal pressure (ICP). Stainless steel bipolar electrodes were positioned on the major pelvic ganglion and their position was adjusted during stimulation until the maximum ICP was obtained. The major pelvic ganglion was stimulated in a step-wise fashion (0 -5 V with 1 volt increments) with a frequency of 12 Hz, for one minute for each voltage. All pressure data were collected for analysis using Polyveiw Data Acquisition software (Astromed, Grass Instrument Division).
Statistics
Data were analyzed using analysis of variance (ANOVA) with post-hoc comparisons made by Student Newman Keul's test. Statistical significance was set at P < 0.05.
Results

Blood pressure
Treatment of SHRSP from six weeks to twelve weeks of age with captopril significantly reduced the systolic blood pressure (109 AE 5.2 vs 191 AE 3.3 mmHg captopril vs placebo treated P < 0.05). Sprague Dawley rats were confirmed normotensive with a systolic blood pressure of 121 AE 2.5 mmHg. The resting MAP under anesthesia was lower in the SHRSP treated with captopril than in the placebo treated SHRSP (58 AE 2.0 vs 166 AE 36 mmHg captopril treated vs placebo P < 0.05). The control normotensive animals had a MAP of 90 AE 2.3 mmHg during anesthesia.
Erectile response
The responsiveness of the vasculature to the stimulation of the major pelvic ganglion was assessed by measurement of ICP=MAP. Figure 1 shows the stepwise increase in ICP=MAP during stimulation of the major pelvic ganglion over the range of 0 (no stimulation) to 5 volts for control rats and placebo treated SHRSP. There was no significant difference between the ICP=MAP for the placebo treated SHRSP and normotensive rats at the lower voltages (1, 2 and 3 volts). At 4 and 5 volts stimulation, however, there was a significant impairment of the erectile response in the placebo treated SHRSP. Figure 2 shows the erectile responsiveness to stimulation of the major pelvic ganglion in the placebo and captopril treated SHRSP. Again there was no difference in the ICP=MAP between the two groups at the lower stimulation voltages. Stimulation with 4 or 5 volts produced a significant enhancement of the erectile response in the captopril treated SHRSP compared to the placebo treated SHRSP. 
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Discussion
This study confirms in an animal model of essential hypertension the link between hypertension and erectile dysfunction. Also, the study suggests that treatment of hypertension with an ACE inhibitor is beneficial to the erectile dysfunction. The captopril treated rats had an improved erectile response despite a considerably lower MAP. The increased blood flow into the cavernous sinuses required for erection is ultimately driven by the force from the MAP, therefore in conditions where the MAP is low, as in the captopril treated rats, it is possible that the erectile response could be impaired. 9 The fact that this is not the case suggests that the beneficial effects of the captopril treatment override any deleterious effects of the reduction in MAP.
A cause of erectile dysfunction is disturbance of the blood flow into the erectile tissue. Arterial occlusive disease can decrease the perfusion pressure and arterial flow into the cavernous spaces, this decreases the rigidity of the erect penis. 10, 11 Various studies have suggested that blood vessels undergo a structural change during hypertension. 12, 13 These changes include an increase in vessel wall thickness as well as a reduction in the diameter of the blood vessel lumen. These slow pressor mechanisms have been proposed to account of many of the long-term changes in vascular resistance which are associated with hypertension. Vascular resistance in an intact vessel is a function of lumen diameter, the number and length of the blood vessels and the blood viscosity; in hypertension, the changes in lumen size appear to be the most important determinant of vascular resistance. Hypertension is often associated with aberrant smooth muscle cell proliferation in the systemic vasculature and this is thought to be responsible in part for the reduction in the size of the blood vessel lumen. Such increases in smooth muscle cells numbers could affect the erectile response by reducing the blood flow into the cavernous sinuses was well as reducing the compliance of the cavernous sinus thus leading to a defect in the venocclusive mechanism required for the maintenance of erection. Recently it has been shown that the penile vascular resistance is higher in SHR than Sprague Dawley rats. 14 Also, studies have shown that there is an increase in the smooth muscle cell numbers in the corpus cavernosum for spontaneously hypertensive rats (SHR) compared to control animals. There was a positive correlation between the amount of cavernosal smooth muscle cells proliferation and the systolic blood pressure in these animals. There was also in increase in the connective tissue surrounding nervous tissue in the cavernosum. 15 Thus the increase in smooth muscle cell proliferation would both reduce the blood flow to the penis as well as reducing the compliance of the cavernous sinuses and the combination of these may be responsible for erectile dysfunction.
Many studies have suggested that the increase in smooth muscle cell proliferation in the hypertensive rat is due to an increase responsiveness of the smooth muscle cells to the mitogenic effects of angiotensin II. 16, 17 Thus by inhibiting the local and systemic production of angiotensin II it is possible that there was a reduction in smooth muscle proliferation in the corpus cavernosum and that this is responsible for the improved erectile response with captopril treatment. Studies have shown in SHR that two weeks of treatment with the ACE inhibitor, Enalapril, reduced the penile vascular resistance. 18 This appeared to be independent of the blood pressure lowering effects on the ACE inhibitor as a similar reduction in blood pressure with other antihypertensive agents did not result in as significant a change in the penile vasculature.
Another possible mechanism for the beneficial effect of ACE inhibition relates to the vasoactive properties of angiotensin II. ACE is responsible both for the production of angiotensin II, a vasoconstrictor, and the degradation of bradykinin, a vasodilator. Both of these vasoactive mechanisms have been shown to be active in the human corpus cavernosum. 7 In fact, it appears that cavernous smooth muscle tone is partially controlled by a balance of bradykinin induced relaxation and angiotensin II induced constriction. Various studies have suggested that the systemic vasculature contains a local renin angiotensin system. The presence of a local angiotensin II generating system in the penis has been supported by studies which suggest that in humans the corpus canvernosum produces physiologically relevant amount of angiotensin II. The levels produced appear to be higher in detumescence when the cavernous smooth muscle is constricted. 7 Angiotensin II also appears to be important for the maintenance of erection since detumescence results from intracavernosal injection of Angiotensin II in dogs. 19 Therefore it would seem plausible that by reducing circulating angiotensin II and increasing circulating bradykinin by ACE inhibition, the erectile response would be increased.
This study would suggest that ACE inhibitors do not have deleterious effect in erectile function in rats despite a marked reduction in mean arterial pressure. The possibility that this is due to a reduction in smooth muscle cell proliferation and contraction warrants further investigation.
